Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 13/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645838 | 1.00 | GPR84 (0.36) | GPR84MMP3MAPTALDH1A1ADRA2A | |
| SCHEMBL24806625 | 0.98 | GPR84 (0.37) | GPR84MMP3MAPT | |
| SCHEMBL21230892 | 0.95 | ALDH1A1 (0.36) | GPR84MAPTALDH1A1HCAR3KDM4E | |
| SCHEMBL21472499 | 0.95 | ALDH1A1 (0.36) | GPR84MAPTALDH1A1HCAR3KDM4E | |
| SCHEMBL21231037 | 0.87 | GAA (0.32) | KDM4EGAA | |
| SCHEMBL22645834 | 0.87 | GAA (0.32) | KDM4EGAA | |
| SCHEMBL21842818 | 0.87 | GPR84 (0.41) | GPR84MAPTALDH1A1ADRA2ATSHR | |
| SCHEMBL22646004 | 0.87 | MMP3 (0.40) | GPR84MMP3MAPTALDH1A1TSHR | |
| SCHEMBL22645821 | 0.86 | GPR84 (0.36) | GPR84MMP3MAPTADRA2AHCAR3 | |
| SCHEMBL22645852 | 0.86 | GPR84 (0.36) | GPR84MMP3MAPTADRA2AHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2021155267-A2 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2020227510-A1 | POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227537-A1 | DIFFERENTIALLY EXPRESSED IMMUNE CELL MICRORNAS FOR REGULATION OF PROTEIN EXPRESSION | Modernatx, Inc (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | GPR84 3071/4885MMP3 1409/4885MAPT 2204/4885 |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | GPR84 3071/4885MMP3 1409/4885MAPT 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.